4DMedical Wins Cleveland Clinic as Third Major U.S. Adopter of CT:VQ Imaging

4DMedical Ltd ( (AU:4DX) ) has provided an announcement.

4DMedical has secured a commercial agreement for its CT:VQ respiratory imaging solution with Cleveland Clinic, one of the United States’ most prominent hospitals, marking the third major U.S. academic medical centre to adopt the technology since its FDA clearance. The deployment, which begins with a month of introductory pricing before moving to full commercial terms, strengthens 4DMedical’s strategy to establish CT:VQ as a standard of care in leading academic medical centres and positions Cleveland Clinic as a key reference site, alongside Stanford University and the University of Miami, to demonstrate the technology’s clinical and operational advantages over traditional nuclear VQ imaging and support wider adoption across health systems and community hospitals.

The most recent analyst rating on (AU:4DX) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.

More about 4DMedical Ltd

4DMedical Limited (ASX:4DX) is a global medical technology company focused on revolutionising respiratory care through advanced imaging and artificial intelligence. Its patented XV Technology transforms standard medical scans into detailed functional lung insights, supporting earlier and more precise detection, diagnosis and monitoring of respiratory disease. The company’s software portfolio includes FDA-cleared XV Lung Ventilation Analysis Software, CT LVAS and its flagship CT:VQ solution, all delivered via a SaaS model that integrates with existing hospital infrastructure to enhance physician productivity and enable more personalised patient care.

Average Trading Volume: 5,147,203

Technical Sentiment Signal: Buy

Current Market Cap: A$1.55B

For an in-depth examination of 4DX stock, go to TipRanks’ Overview page.